Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
18.08
Nov 16 • 3:59 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
2.90B
Enterprise Value
2.42B
Income
-314.42M
Sales
21.38M
Book/sh
5.78
Cash/sh
3.22
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
503
IPO
Dec 08, 2017
P/E
-
Forward P/E
-
PEG
-
P/S
135.55
P/B
3.13
P/C
5.61
P/FCF
-
EV/EBITDA
-
EV/Sales
113.05
Quick Ratio
5.94
Current Ratio
6.21
Debt/Eq
0.04
LT Debt/Eq
0.03
Option/Short
Yes / Yes
EPS (ttm)
-1.74
EPS next Y
-2.27
EPS next Q
-0.61
EPS this Y
41.10%
EPS next Y
-29.63%
EPS next 5Y
16.85%
EPS past 3/5Y
-4.56% -
Sales past 3/5Y
- -
EPS Y/Y TTM
40.59%
Sales Y/Y TTM
-
EPS Q/Q
149.61%
Sales Q/Q
-
Insider Own
6.34%
Insider Trans
-0.18%
Inst Own
98.28%
Inst Trans
0.99%
ROA
-27.20%
ROE
-33.94%
ROIC
-33.06%
Gross Margin
21.42%
Oper. Margin
-2488.14%
Profit Margin
-1470.50%
SMA20
-6.03%
SMA50
-8.18%
SMA200
-14.75%
Trades
Shs Outstand
160.26M
Shs Float
150.12M
52W High
27.30 -33.77%
52W Low
15.34 17.86%
Volatility
4.06% 4.50%
ATR (14)
0.88
RSI (14)
39.18
Beta
1.08
Rel Volume
0.00
Avg Volume
1.61M
Volume
0
Perf Week
-11.07%
Perf Month
2.67%
Perf Quarter
-25.63%
Perf Half Y
-1.74%
Perf YTD
9.51%
Perf Year
3.67%
Perf 3Y
-0.28%
Perf 5Y
-64.15%
Perf 10Y
-
Prev Close
18.08
Price
18.08
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$35.82
Implied Upside
+98.1%
Analysts17incl. previous ratings
Rating Distribution15 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 13, 2026Initiated
WFC logoWWells Fargo
Overweight$35+93.6%
Jul 13, 2026Resumed
JPM logoJJP Morgan
Overweight$29+60.4%
Mar 26, 2026Reiterated
HH.C. Wainwright
Buy$32 → $42+132.3%
Feb 24, 2026Initiated
WWolfe Research
Peer Perform
Jan 07, 2026Resumed
UBS logoUUBS
Buy$25+38.3%
Apr 10, 2025Upgrade
CCantor Fitzgerald
Neutral → Overweight
Mar 07, 2025Resumed
MS logoMMorgan Stanley
Overweight$41 → $33+82.5%
Feb 11, 2025Initiated
DB logoDDeutsche Bank
Buy$31+71.5%
Jan 07, 2025Initiated
RRobert W. Baird
Outperform$31+71.5%
Jan 03, 2025Initiated
WWilliam Blair
Outperform
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chin Peter ScottChief Medical OfficerSep 04 '26Sale22.291,65436,868204,538Sep 09 04:44 PM
Chin Peter ScottOfficerSep 04 '26Proposed Sale22.291,65436,867Sep 04 08:38 PM
Thornberry NancyDirectorSep 02 '26Sale22.9011,439261,92919,686Sep 04 05:02 PM
Schuth Alexander O.COFO and SecretarySep 01 '26Sale23.442,76864,882278,995Sep 03 04:17 PM
NANCY THORNBERRYDirectorSep 02 '26Proposed Sale23.2711,439266,128Sep 02 04:31 PM
ALEXANDER SCHUTHOfficerSep 01 '26Proposed Sale23.762,76865,768Sep 01 04:47 PM
Schuth Alexander O.COFO and SecretaryAug 11 '26Sale25.072,85771,625281,763Aug 13 05:01 PM
Schuth Alexander O.OfficerAug 11 '26Proposed Sale25.072,85771,624Aug 11 05:39 PM
CAROLE HOFormer AffiliateFeb 05 '26Proposed Sale20.2939,490801,394Feb 05 04:14 PM
CAROLE HOFormer AffiliateFeb 04 '26Proposed Sale21.18150,0003,176,970Feb 04 04:16 PM
CAROLE HOFormer AffiliateFeb 03 '26Proposed Sale22.16150,0003,324,060Feb 03 04:47 PM
Watts Ryan J.President and CEOJan 06 '26Sale16.5035,198580,767296,833Jan 08 04:20 PM
Schuth Alexander O.COFO and SecretaryJan 06 '26Sale16.5017,218284,097282,828Jan 08 04:19 PM
Ho CaroleConsultantJan 06 '26Proposed Sale16.5017,218284,097Jan 06 08:28 PM
Schuth Alexander O.OfficerJan 06 '26Proposed Sale16.5017,218284,097Jan 06 08:25 PM
Watts Ryan J.DirectorJan 06 '26Proposed Sale16.5035,198580,767Jan 06 08:24 PM
CAROLE HOOfficerDec 04 '25Proposed Sale19.001,88235,758Dec 04 04:41 PM
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Co-FounderDr. Ryan J. Watts Ph.D.
Ph.D.Dr. Alexander O. Schuth M.D.
Chief Technical and Manufacturing OfficerDr. Dana Andersen
Chief Scientific OfficerMr. Joe Lewcock Ph.D.
General CounselMr. Chris Walsh J.D.